Increased government focus on metabolic disease management and strategic investment by global pharma companies are accelerating product launches and adoption across the region
While these side effects are typically dose-related and often fade over time, they remain the leading reason for early drop-out from clinical trials
Klopp AH, Spaeth EL, Dembinski JL, Woodward WA, Munshi A, Meyn RE, Cox JD, Andreeff M , Marini FC
Frequently Asked Questions How many sessions are needed
Its important to follow your providers guidance to achieve the best outcomes while maintaining safety and effectiveness throughout the treatment
Ohara H, Matsumoto H, Ito K, et al